You just read:

FDA Grants Breakthrough Therapy Designation for Daiichi Sankyo and Plexxikon's Investigational CSF-1R Inhibitor Pexidartinib (PLX3397) in Tenosynovial Giant Cell Tumor

News provided by

Daiichi Sankyo, Inc.

Oct 30, 2015, 11:23 ET